Navigation Links
Vortex Biosciences Announces Publication in Nature Precision Oncology Describing the Genomic and Phenotypic Characterization of CTCs from Prostate Cancer Patients
Date:5/23/2017

Vortex Biosciences, provider of circulating tumor cell (CTC) capture systems, today announced the publication of “Label-free isolation of prostate circulating tumor cells using Vortex microfluidic technology” in Nature Precision Oncology on May 8th. The peer reviewed publication is the result of a collaboration with Dr. Dino Di Carlo and Dr. Matthew Rettig at the University of California, Los Angeles. The publication describes the use of Vortex technology for the isolation and characterization of CTCs from 22 patients with advanced prostate cancer. CTCs can provide both genetic and phenotypic information about tumor evolution, potentially from both primary and metastatic sites. In this paper, the utility of the Vortex technology to support the capture and characterization of CTCs from prostate cancer patients was demonstrated.

The Vortex technology isolates and collects CTCs directly from whole blood based on the greater deformability and larger size of the cells. CTCs are collected unbiased by their molecular characteristics and available for a wide range of analysis, providing a window into a patient’s cancer biology. The paper describes the capturing of CTCs from prostate cancer patients with high purity (from 1.74 to 37.59%) and efficiency (from 1.88 to 93.75 CTCs/7.5mL). Interestingly, atypical large circulating cells were identified in 5 age-matched healthy donors (46-77 years old; 1.25-2.5 CTCs/7.5 mL) but not in 5 healthy donors <30 years-old (21-27 years old; 0.00 CTC/7.5 mL). Using a threshold calculated from the 5 age-matched healthy donors (3.37 CTCs/mL), CTCs were identified at levels above the healthy threshold in 80% of the prostate cancer patients. A fraction of the cells collected (11.5%) did not express epithelial prostate markers (CK and/or PSA) and some instead expressed markers of epithelial-mesenchymal transition (EMT), i.e. vimentin and N-cadherin.

"We are excited to see how effective the Vortex technology is for isolating CTCs independent of their epithelial properties, making them available for both genomic and phenotypic analysis,“ said Dr. Dino Di Carlo, Director of the Microfluidic Biotechnology Laboratory at UCLA and Director of the Cancer Nanotechnology Program of the Jonsson Comprehensive Cancer Center. "The work demonstrated in this paper shows what a powerful window into patient cancer biology CTCs can be with the right collection system."

The fully automated VTX-1 Liquid Biopsy System from Vortex represents the next step in CTC isolation. The Vortex system utilizes a proprietary microfluidic chip to stably trap and capture CTCs in micro-scale vortices based on their larger size and greater deformability than the white and red blood cells. With excellent CTC recovery, best in class CTC purity, and collected CTCs being viable, and ready for downstream analysis, the VTX-1 offers the best CTC samples available today.

About Vortex Biosciences
Vortex Biosciences is a cancer research and diagnostics company that integrates cancer biology, microfluidic engineering and informatics to develop tools for isolating and characterizing circulating tumor cells. The Vortex VTX-1 instrument harvests intact circulating tumor cells from whole blood samples for use in downstream research and clinical applications such as patient stratification in clinical trials, monitoring disease progression and drug treatment effectiveness. With a mission to enable noninvasive diagnosis of cancer and real-time monitoring throughout a patient’s treatment, Vortex is at the forefront of accelerating cancer research and improving patient outcomes. Vortex is a core subsidiary of NetScientific plc, a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercializing technologies that significantly improve the health and well-being of people with chronic diseases. For more information, visit http://www.vortexbiosciences.com.

Read the full story at http://www.prweb.com/releases/2017/05/prweb14354838.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Vortex Biosciences Presents Studies at AACR That Demonstrate Use of the VTX-1 System for Isolating and Analyzing Circulating Tumor Cells for Cancer Research
2. Vortex Biosciences Announces Commercial Launch of Fully Automated System for CTC Isolation
3. CSO of Vortex Biosciences Dr. Elodie Sollier-Christen Awarded With 2017 SLAS Innovation Award
4. Vortex Biosciences Appoints Dr. Massimo Cristofanilli As Chairman of Newly Formed Scientific Advisory Board
5. Vortex Biosciences Inventor Receives Presidential Award for Research Leading to Groundbreaking "Liquid Biopsy" Technique
6. Therapix Biosciences Announces the Appointment of Josh Blacher as Chief Financial Officer
7. ACEA Biosciences Introduces a Multi-Option Configuration NovoCyte® Flow Cytometer
8. Pendant Biosciences Announces Acceptance into JLABS @ Toronto
9. Cancer and Immunotherapy Symposium Hosted by ACEA Biosciences Gathers Clinicians and Scientists From Around the World
10. TOMA Biosciences Releases the COMPASS Tumor Profiling System
11. Kindred Biosciences to Present at 2017 Jefferies Animal Health Summit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... IN (PRWEB) , ... September 22, 2017 , ... ... the Rocky Mountain Hobby-Expo in Denver, Colorado October 28 and 29, 2017, to ... the event is to promote participation in different hobbies, including but not limited ...
(Date:9/21/2017)... ... 21, 2017 , ... Vixiar Medical announced today that it ... to The LaunchPort™ Accelerator at the City Garage in Port Covington. The LaunchPort™, ... business services to its Residents. , Vixiar Medical recently closed a $1.5 ...
(Date:9/21/2017)... ... (PRWEB) September 21, 2017 , ... The ... congress to review the latest knowledge on these products, which are increasingly used ... discuss the impact of Biostimulants on Plant Nutrition, Abiotic Stresses, Plant Growth and ...
(Date:9/21/2017)... UK (PRWEB) , ... September 21, 2017 , ... ... a QuintilesIMS company, who enable the world’s most progressive pharma and biotech organizations ... clinical trials at top pharma and biotech events in Q4. , DrugDev will ...
Breaking Biology Technology:
(Date:6/14/2017)... -- IBM (NYSE: IBM ) is introducing several innovative partner ... developing collaboration between startups and global businesses, taking place in ... event, nine startups will showcase the solutions they have built ... France is one of ... 30 percent increase in the number of startups created between ...
(Date:5/16/2017)...   Bridge Patient Portal , an enterprise ... EMR Systems , an electronic medical record solutions ... established a partnership to build an interface between ... Centricity™ products, including Centricity Practice Solution (CPS), Centricity ... new integrations will allow healthcare delivery networks using ...
(Date:4/19/2017)... York , April 19, 2017 ... as its vendor landscape is marked by the presence ... market is however held by five major players - ... Together these companies accounted for nearly 61% of the ... the leading companies in the global military biometrics market ...
Breaking Biology News(10 mins):